Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PSMD10 encodes a subunit of the PA700/19S complex, which is the regulatory component of the 26S proteasome. Additionally we are shipping Proteasome (Prosome, Macropain) 26S Subunit, Non-ATPase, 10 Kits (19) and Proteasome (Prosome, Macropain) 26S Subunit, Non-ATPase, 10 Proteins (18) and many more products for this protein.
Showing 10 out of 83 products:
Mouse (Murine) Polyclonal PSMD10 Primary Antibody for WB - ABIN611034
Hay, Chao, Kuo, Scheller: Protein interactions regulating vesicle transport between the endoplasmic reticulum and Golgi apparatus in mammalian cells. in Cell 1997
Show all 3 references for ABIN611034
Human Polyclonal PSMD10 Primary Antibody for WB - ABIN1944780
Ota, Suzuki, Nishikawa, Otsuki, Sugiyama, Irie, Wakamatsu, Hayashi, Sato, Nagai, Kimura, Makita, Sekine, Obayashi, Nishi, Shibahara, Tanaka, Ishii, Yamamoto, Saito, Kawai, Isono, Nakamura, Nagahari et al.: Complete sequencing and characterization of 21,243 full-length human cDNAs. ... in Nature genetics 2003
Show all 2 references for ABIN1944780
Human Polyclonal PSMD10 Primary Antibody for WB - ABIN2786729
Umemura, Itoh, Itoh, Yamaguchi, Nakajima, Higashitsuji, Onoue, Fukumoto, Okanoue, Fujita: Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma. in Hepatology (Baltimore, Md.) 2008
This study is the first to report gankyrin as a potential link between microRNAs and liver steatosis in zebrafish.
Gankyrin-overexpressed non-small cell lung cancer patients had a significantly shorter survival time
Results identified rs111638916 SNP in the PSMD10 3'-UTR (show UTS2R Antibodies) as a risk factor for gastric cancer (GC) and acted as a tumor promoting factor. SNP rs111638916 was also regulated by miR (show MLXIP Antibodies)-505, resulting in its up-regulation in patients with GA and AA genotypes.
p28GANK expression was increased in metastatic ESCC tissues and cells, and p28GANK knockdown decreased the metastatic ability of ESCC cells.
This study identifies gankyrin, for the first time, as new potential predictive and oncogenic factor of well-differentiated/dedifferentiated liposarcoma, suggesting the potential for service as a future Liposarcoma therapeutic approach.
On the base results of present study one can suggests the p28GANK being useful as a predictive marker for patient prognosis and a novel therapeutic target for gastric cancer.
IL-1beta (show IL1B Antibodies) stimulation causes sequential phosphorylation of IRAK-1 (show IRAK1 Antibodies), c-Jun N-terminal kinase, and p300 (show EP300 Antibodies) and enhances recruitment of the p300/CBP (show CREBBP Antibodies)/NF-Y complex to Gankyrin promoter
Gankyrin is aberrantly expressed beginning at the initiation stage and plays an important role in the initiation, promotion, and progression of hepatocarcinogenesis.
Gankyrin may be functional in cervical carcinogenesis and metastasis.
MiR (show MLXIP Antibodies)-605 directly targets and represses PSMD10 expression.
The intensity of gankyrin expression was 'positive' in two cases (20%) and 'strongly positive' in eight cases (80%).
the present study clarified, at least partly, mechanisms of vascular tumorigenesis, and suggests that gankyrin might play a physiological role in hypoxic responses besides its roles as an oncoprotein.
FXR (show NR1H4 Antibodies) prevents liver cancer by inhibiting the gankyrin promoter via C/EBPbeta (show CEBPB Antibodies)-HDAC1 (show HDAC1 Antibodies) complexes, leading to subsequent protection of tumor suppressor proteins from degradation.
Gankyrin is a key regulator of Ras-mediated activation of Akt through inhibition of the downstream RhoA/ROCK pathway and thus plays an essential role in Ras-induced tumorigenesis.
Findings suggest that retinoblastoma protein degradation in Lmna (show LMNA Antibodies)-/- cells occurs by gankyrin and MDM2 (show MDM2 Antibodies)-independent mechanisms.
Gankyrin oncoprotein has a role in progression of esophageal squamous cell carcinoma
This gene encodes a subunit of the PA700/19S complex, which is the regulatory component of the 26S proteasome. The 26S proteosome complex is required for ubiquitin-dependent protein degradation. This protein is a non-ATPase subunit that may be involved in protein-protein interactions. Aberrant expression of this gene may paly a role in tumorigenesis. Two transcripts encoding different isoforms have been described. Pseudogenes have been identified on chromosomes 3 and 20.
26S proteasome non-ATPase regulatory subunit 10
, proteasome 26S subunit, non-ATPase, 10
, 26S proteasome regulatory subunit p28
, ankyrin repeat protein
, hepatocellular carcinoma-associated protein p28-II
, proteasome subunit p28
, proteosome (prosome, macropain) 26S subunit, non-ATPase, 10
, proteosome subunit p28
, proteasome 26S non-ATPase subunit 10